Sogo Katsumasa, Sogo Masanobu, Okawa Yoshie
Sogo PTSD Institute, Medical Corporation Sogokai, Hiroshima-city, Japan.
Brain Behav. 2021 Jun;11(6):e02147. doi: 10.1002/brb3.2147. Epub 2021 May 14.
Following a case study on scopolamine butyl bromide, an anticholinergic drug, we studied the effect of a central anticholinergic drug on post-traumatic stress disorder (PTSD)-related flashbacks and nightmares.
We administered trihexyphenidyl (TP) to 34 patients with refractory PTSD-related nightmares and flashbacks (open-label trial [n = 22]; single-blind trial [n = 12]), who had previously received psychiatric treatment for approximately 2-15 years, without therapeutic benefits. The effect of TP was determined using the Clinician-Administered PTSD Scale (CAPS) and the Impact of Event Scale-Revised (IES-R).
Overall, most patients reported an improvement to none or mild on the CAPS for nightmares (88%) and flashbacks (79%).
This study is the first to demonstrate the potential efficacy of TP in the treatment of refractory PTSD-related nightmares and flashbacks. Further double-blind, randomized control trials are needed to explore the potential clinical benefits of TP in PTSD.
在对一种抗胆碱能药物丁溴东莨菪碱进行案例研究之后，我们研究了一种中枢性抗胆碱能药物对创伤后应激障碍（PTSD）相关闪回和噩梦的影响。
我们对34例患有难治性PTSD相关噩梦和闪回的患者给予苯海索（TP）（开放标签试验[n = 22]；单盲试验[n = 12]），这些患者此前接受了约2至15年的精神治疗但未获治疗益处。使用临床医生施测的PTSD量表（CAPS）和事件影响量表修订版（IES-R）来确定TP的效果。
总体而言，大多数患者报告称在CAPS量表上，噩梦（88%）和闪回（79%）改善为无或轻度。
本研究首次证明了TP在治疗难治性PTSD相关噩梦和闪回方面的潜在疗效。需要进一步进行双盲随机对照试验，以探索TP在PTSD中的潜在临床益处。
